Tolerance, not benefit

The Gram Level Where Inulin Stops Helping And Starts Causing Gas

This site has a separate article tracking the dose where published inulin trials found a benefit. This one tracks a different dependent variable from the same trial set: the dose where those trials report gas, bloating or flatulence. Marteau's constipated-elderly trial notes mild flatulence at 15 grams a day.

By SodaTide Team · Last updated September 30, 2026 · 10 min read · Tolerance, not benefit · Reviewed by Dr. Wendy Scinta, MD

A different question than “did it work”

This site has already published an article tracking the dose at which published chicory inulin trials produced a measured benefit — five grams a day to raise bifidobacteria, sixteen grams to move energy intake, ten grams in the same study to do neither. That article answers a question shaped like: how much do you need for something good to happen? This article uses the same body of trials cited on this site's ingredients page to answer a differently shaped question: how much is enough for something uncomfortable to start happening, specifically gas, bloating or flatulence?

Those are not two ways of asking the same thing. A dose that produces a measurable benefit and a dose that produces a noticeable side effect are two separate dependent variables, and a single trial can report on either, both, or neither, depending on what the investigators actually measured and chose to publish. Reading the tolerance side of this literature separately from the benefit side is the entire point of this article.

Why a fermentable fibre produces gas at all

Inulin reaches the colon undigested precisely because it is a prebiotic — the same property that makes it useful to resident bacteria as food is what makes it a source of fermentation gas. When colonic bacteria ferment a fermentable carbohydrate, they produce short-chain fatty acids as a primary output, but fermentation is not a clean, gas-free process. Hydrogen, carbon dioxide and, in some individuals, methane are ordinary byproducts of the same bacterial metabolism that produces the short-chain fatty acids a prebiotic is sold on. More fermentable substrate delivered to the colon in a given period generally means more total fermentation activity, and more fermentation activity generally means more gas produced in that same period. This is basic digestive physiology, not a flaw specific to inulin or to any one brand, and it applies in some degree to every fermentable fibre this site covers, including the resistant starch discussed elsewhere on this blog.

What varies between individuals, and between trials, is the threshold at which that gas production becomes noticeable or uncomfortable rather than simply present. Gut bacterial populations differ from person to person, and a dose that one person's colony ferments quietly can produce noticeable distension in someone else's.

Why inulin sits in a well-known category for gut sensitivity

Inulin belongs to a broader class of short-chain carbohydrates that a large body of gastroenterology research groups together under the FODMAP framework — fermentable oligosaccharides, disaccharides, monosaccharides and polyols, a category built specifically around the observation that these molecules are rapidly fermented by colonic bacteria and reliably associated with gas, bloating and, in sensitive individuals, discomfort when eaten in enough quantity. Fructans, the chemical family inulin belongs to, are one of the recognised FODMAP subgroups. This does not mean inulin is harmful or that FODMAP status is itself a warning label; the FODMAP framework exists mainly to help people with diagnosed digestive conditions identify which foods are more likely to trigger symptoms for them specifically, and plenty of people tolerate fructans in ordinary quantities without any issue at all.

What the FODMAP framework does confirm, independent of any single dose-response trial, is that the mechanism this article describes — more fermentable substrate, more fermentation gas — is not a quirk of the specific trials cited on this site. It is a recognised, well-studied property of this entire class of carbohydrate, and inulin's membership in that class is exactly why a dose that produces a clear prebiotic benefit in a published trial is also a dose worth reading for its tolerance profile, not just its benefit profile.

What the Marteau trial actually reported

Marteau and colleagues, running a double-blind controlled trial of chicory inulin in constipated elderly people, gave 15 grams a day for four weeks. The trial's own published findings, as this site's ingredients page already records, were more bifidobacteria, less difficulty with constipation — and mild flatulence reported. That last clause is the one this article is built around: a trial cited on this site for its benefit findings also documented, in the same published record, a tolerance finding at the same dose.

Fifteen grams a day is worth placing on the same scale as the benefit-threshold doses this site's other article already covers. It sits above the five-gram dose that raised bifidobacteria in Kolida's trial and above the eight-gram dose that did the same with a higher response rate. It sits below the sixteen-gram dose that moved energy intake in Verhoef's crossover. Mild flatulence at fifteen grams does not, on its own, establish a single universal tolerance threshold for inulin generally — trial populations, durations, and inulin sources differ enough that a single number should not be over-generalised — but it is a genuine, published data point placing a tolerance effect inside the same dose range this site's benefit-tracking article already maps in detail.

What the other cited trials do, and do not, say about tolerance

Honesty about this literature requires being equally clear about its limits. This site's ingredients page cites Kolida's bifidogenic-dose trial, Micka's bowel-function trial, and Verhoef's appetite-and-energy-intake crossover alongside Marteau's constipation trial, and only Marteau's published summary, as recorded on this site, explicitly notes a tolerance side effect at the dose given. That does not mean the other three trials found perfect tolerance at every dose tested; published abstracts routinely emphasise the primary outcome a trial was designed to measure and do not always break out secondary tolerance data in the same summary. It means this site's own citation record, sourced from each paper's own abstract, does not currently support printing a specific flatulence or bloating figure for Kolida's 5 g and 8 g doses, for Micka's 12 g dose, or for Verhoef's 10 g and 16 g doses, the way it can for Marteau's 15 g dose.

That gap is itself worth stating plainly rather than papering over with an invented number. A reader who wants a complete tolerance profile across every dose in this table would need to go beyond what this site's existing citations establish, into each trial's full published methods and results sections, or into the wider clinical and observational literature on inulin tolerance specifically. What this article can responsibly offer is the one concrete, already-sourced data point this site has, set in its proper context, rather than a false impression of precision the underlying sources do not support.

How this compares to the formula's other fermentable ingredient

SodaTide's formula names two fermentable carbohydrates that behave similarly in the colon once they arrive there: chicory root inulin and potato resistant starch, covered separately on this site's article on how cooked-and-chilled potato becomes resistant. Both reach the colon largely intact and are fermented by resident bacteria, and both, by the same general physiology described above, can produce fermentation gas as dose increases. This site's ingredients page does not currently carry a resistant-starch tolerance citation as specific as Marteau's flatulence note for inulin, which is a genuine gap in what can be reported here rather than evidence that resistant starch is better tolerated — it may simply reflect which outcomes each cited trial chose to publish in its abstract.

What can be said honestly is that a formula combining two fermentable carbohydrates, even at whatever combined amount this capsule actually delivers, is combining two substrates capable of contributing to the same kind of fermentation-gas response, rather than two unrelated mechanisms. Whether that combination meaningfully changes the tolerance picture relative to either ingredient alone is not something the trial set cited on this site, each testing a single ingredient in isolation, can directly answer.

The same trial set, read for a different outcome

Doses and benefit findings as recorded on this site's ingredients page. The tolerance column reflects what each paper's own abstract discloses on that specific axis, not an assumption about what a fuller methods section might contain.

Reading the table this way rather than the benefit-only way makes a specific gap visible: the trial set this site already cites brackets a benefit range from five to sixteen grams a day, and inside that same range, the single explicit tolerance data point sits at fifteen grams. That is consistent with the general physiology above — more fermentable substrate, more fermentation activity, a rising chance of a noticeable gas effect — without this site overstating a threshold the underlying trials were not all designed to establish with equal precision.

What this means for someone actually taking a fermentable fibre

The practical takeaway is not that inulin is dangerous at any of these doses; nothing in this trial set suggests that, and Marteau's own finding was mild flatulence, not a safety signal. The takeaway is that gas and bloating in the first stretch of taking a fermentable fibre are an expected, physiologically ordinary response to fermentation working as intended, not necessarily a sign that a product disagrees with a given person specifically. This site's other articles on fermentable ingredients make the same point from the mechanism side: a tolerance response is what fermentation of a novel substrate typically looks like at first, particularly before resident bacterial populations have adjusted to a new, regular substrate supply.

For a capsule that prints no gram figure at all, this creates a specific, practical problem distinct from the benefit question this site's other article addresses: a buyer cannot use this trial set to predict where their own dose sits relative to the tolerance range mapped above, because the label does not say how many grams of inulin, if any meaningful amount, a single capsule actually delivers. The gap this article is built around and the gap this site's benefit-dose article is built around are, in that sense, the same missing number, read for two different consequences.

References